# breast cancer - gpt-5.6-luna

- Benchmark system: E2seq + Agent RAG
- Repeat: 3
- Task type: PROGNOSIS
- Tissue / sample source: breast tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: OpenAI / gpt-5.6-luna
- Message SHA-256: 2eef237c25053f55d87c73e963368cae88b5c698447f11e7e98ebc594d62e5bb
- Response HTTP status: 200
- Prompt tokens: 30826
- Completion tokens: 11864
- Reasoning tokens: 0
- Total tokens: 42690
- API requests reported: 2
- Elapsed seconds: 158.941
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 685.605
- Question handoff seconds: 699.996
- Final benchmark system: E2seq; file rank 3/5; original repeat 3; model vendor: OpenAI

---
## Data-quality and statistical interpretation warning

The ledger reports **100 unique genes** among **106 retained rows**, with **6 duplicated gene/probe rows**; **52 are risk-associated (HR > 1)** and **48 protective-associated (HR < 1)**. All 100 unique genes have **P ≤ 0.05 and FDR ≤ 0.05**, with FDR values from **4.4762322e-10 to 1.7414147e-06**. This unusually broad and uniformly strong significance, together with generally modest effect sizes—approximately **HR 1.183–1.261** for risk-associated genes and **HR 0.793–0.839** for protective-associated genes—is technically suspicious and should be checked for sample-size inflation, duplicated or correlated probes, leakage between training and testing data, unadjusted clinical confounding, or an over-optimistic survival model.

The results are therefore best interpreted as **strong within-cohort prognostic associations**, not as independently validated biomarkers. **External statistical validation was not performed.** The pathway, interaction, tissue, disease, and literature records below are contextual evidence and do not constitute replication or a newly calculated enrichment analysis.

## 1. Overall biological interpretation

The dominant prognostic pattern is a contrast between:

1. A **risk-associated proliferative and mitotic program**, represented by coordinated associations for **PKMYT1, RACGAP1, KIF20A, CDCA5, TPX2, KIF4A, UBE2C, CCNE2, PTTG1, AURKA, CDC20, ZWINT, NUSAP1, UBE2S, and PRC1**.
2. A **protective-associated immune and stromal/epithelial composition program**, represented by **FCER1A, JCHAIN, STAT5A, STAT5B, CD1C, CD1E, KLRB1, FLT3, IL27RA, COL17A1, OGN, LAMA2, COL14A1, MFAP4, and ADAMTS8**.
3. Additional risk associations involving **RNA/protein regulation, cell signaling, cytoskeletal behavior, and metabolism**, including **LARP1, STIP1, GSK3B, EZR, CPT1A, GPRC5A, S100P, and WNT7B**.

This pattern is compatible with poorer OS being associated with tumors showing greater cell-cycle activity and possibly altered signaling/metabolic adaptation, whereas protective associations may partly reflect retained epithelial differentiation, extracellular-matrix architecture, or increased immune/stromal representation. However, because the analysis uses bulk breast tumor tissue, the protective genes cannot presently be distinguished from markers of favorable tumor-cell state versus markers of nonmalignant immune or stromal cells.

## 2. Core biological programs

### Program 1: Mitotic progression, chromosome segregation, and cell-cycle activation

- **Association:** Predominantly **risk-associated**.
- **Major genes:** **PKMYT1, RACGAP1, KIF20A, TROAP, CDCA5, TK1, TPX2, KIF4A, UHRF1, UBE2C, CCNE2, PTTG1, FEN1, CENPO, CKAP2L, NUSAP1, UBE2S, PRC1, CDC20, AURKA, and ZWINT**.
- **Relevant standardized pathways:**  
  - **KEGG: Cell cycle**
  - **GO: Positive regulation of mitotic nuclear division (GO:0045840)**
  - Related Hallmark concepts: **E2F targets**, **G2/M checkpoint**, and **mitotic spindle**.

These genes span multiple stages of proliferation rather than representing a single marker: cyclin-dependent progression, DNA replication and repair, spindle assembly, cytokinesis, kinetochore function, and ubiquitin-mediated mitotic control. The retrieved network records also connect selected genes to **PLK1, TPX2, ANAPC2, BUB1B, CDC20, and DLGAP5**, supporting a coherent mitotic network.

**Evidence strength:**  
- **Direct dataset:** strong and internally coherent; multiple genes have risk HRs around 1.18–1.24 and very small FDR values.  
- **Pathway evidence:** consistent with the supplied KEGG and GO annotations.  
- **Network evidence:** STRING associations support network-level coherence, but the supplied records do not establish that every relationship is a direct physical interaction.  
- **Limitation:** proliferation may be a prognostic proxy for tumor grade, stage, subtype, or treatment sensitivity rather than an independent causal mechanism. Formal pathway enrichment statistics were not recalculated during synthesis.

### Program 2: RNA/protein homeostasis, stress adaptation, and growth signaling

- **Association:** Predominantly **risk-associated**.
- **Major genes:** **LARP1, STIP1, GSK3B, ATP2A2, USP30, UTP23, DDX41, PSMD3, TIMELESS, YTHDF1, ALG3, ZFP91, TRIB3, and GPI**.
- **Relevant pathway concepts:**  
  - GO terms involving **ubiquitin-protein ligase or ubiquitin-transferase activity**
  - **RNA binding**, **protein binding**, and cellular stress/signaling processes
  - **KEGG: ErbB signaling**, **cell cycle**, and related intracellular signaling annotations for GSK3B.

The combination suggests that poor survival may be associated with increased RNA processing or translation control, protein turnover, stress tolerance, and growth-related signaling. **LARP1** and **YTHDF1** are compatible with post-transcriptional regulation, while **STIP1**, **USP30**, and **PSMD3** point toward chaperone, deubiquitination, or proteasome-related biology. **GSK3B** provides a plausible signaling bridge because the supplied annotations link it to intracellular signaling, apoptosis regulation, ErbB signaling, and the β-catenin regulatory system.

**Evidence strength:**  
- **Direct dataset:** moderate to strong for association, because several functionally related genes are risk-associated.  
- **Pathway/ontology:** supportive but broad; “protein binding” and related high-level terms are not mechanistically specific.  
- **Literature:** the supplied PubMed record reports that STIP1 correlates with tumor immune infiltration and prognosis in pan-cancer analysis (PMID **37488801**), but this is not an independent validation of the current breast-cancer cohort.  
- **Limitation:** this may be a general high-stress or high-proliferation signature rather than a distinct prognostic mechanism.

### Program 3: Immune-cell and immune-signaling representation

- **Association:** Predominantly **protective-associated**.
- **Major genes:** **FCER1A, JCHAIN, STAT5A, STAT5B, CD1C, CD1E, KLRB1, FLT3, IL27RA, and ADGRG1**.
- **Relevant pathway concepts:** immune-cell activation, antigen presentation, cytokine signaling, and **STAT-related signaling**.

The presence of **FCER1A, CD1C, and CD1E** is compatible with dendritic-cell or antigen-presenting-cell representation; **KLRB1** suggests lymphoid or innate-like immune populations; **JCHAIN** may indicate antibody-producing cell representation; and **FLT3, IL27RA, STAT5A, and STAT5B** support immune cytokine or hematopoietic signaling. The retrieved network records place **FLT3, LEPR, STAT5A, and STAT5B** around a STAT3-centered network, but this is a network association rather than proof of direct regulation by STAT3.

**Evidence strength:**  
- **Direct dataset:** strong for protective association; for example, **FCER1A HR=0.7932319, FDR=1.7692578e-09**, **JCHAIN HR=0.80290118, FDR=1.7692578e-09**, **CD1C HR=0.81422548, FDR=3.1466298e-07**, and **KLRB1 HR=0.82162453, FDR=3.5633368e-07**.  
- **Expression/tissue evidence:** biologically compatible with immune-cell representation in bulk tumor samples.  
- **Literature:** the supplied PROS1 study linked prognosis with immune-cell infiltration in breast cancer (PMID **37827342**), although PROS1 itself is protective-associated here (**HR=0.83621827; FDR=1.0775537e-06**) and the publication does not validate this exact multigene pattern.  
- **Major limitation:** the signal may primarily reflect immune abundance or tumor purity rather than tumor-cell-intrinsic protective biology.

### Program 4: Epithelial differentiation, extracellular matrix, and tissue architecture

- **Association:** Predominantly **protective-associated**.
- **Major genes:** **COL17A1, OGN, CLDN11, TP63, LAMA2, PCDH18, ADAMTS8, RELN, MFAP4, PDGFRA, COL14A1, RBP7, and IGFBP6**.
- **Relevant pathway concepts:**  
  - **GO: extracellular region**
  - extracellular matrix organization and cell-adhesion concepts
  - epithelial junction and basement-membrane biology.

The group combines epithelial-associated genes such as **COL17A1, CLDN11, TP63, and PCDH18** with matrix-associated genes such as **LAMA2, OGN, COL14A1, MFAP4, and ADAMTS8**. Collectively, this is more consistent with preserved tissue organization, epithelial differentiation, and/or a stromal compartment associated with less aggressive disease than with a single linear pathway.

**Evidence strength:**  
- **Direct dataset:** coherent protective direction across many matrix, adhesion, and epithelial genes.  
- **Ontology/tissue evidence:** compatible with extracellular-region and plasma-membrane annotations supplied for the cohort.  
- **Disease/literature:** external records provide general disease and expression context, but no independent breast-cancer OS statistic was supplied for this program.  
- **Major limitation:** matrix and epithelial signals are especially vulnerable to tumor purity and differences in stromal composition. The protective association may therefore be compositional.

### Program 5: Cytoskeletal remodeling, signaling, and metabolic adaptation

- **Association:** Mainly **risk-associated**, with some potentially counterbalancing protective genes.
- **Major genes:** **EZR, RALGAPB, RACGAP1, CPT1A, GPRC5A, S100P, WNT7B, CFL1, and ATP2A2**; protective-associated contextual genes include **IGF1, IGFBP6, and LEPR**.
- **Relevant pathway concepts:** cytoskeletal organization, cell motility, membrane signaling, fatty-acid oxidation, and Wnt-related signaling.

**EZR, RACGAP1, and CFL1** are compatible with cytoskeletal and cell-movement phenotypes, while **CPT1A** suggests altered fatty-acid utilization. **GPRC5A, S100P, WNT7B, and GSK3B** provide plausible links to epithelial signaling, Wnt/β-catenin regulation, and tumor-state adaptation.

**Evidence strength:**  
- **Direct dataset:** supportive but less specific than the mitotic program.  
- **Pathway/network evidence:** plausible based on gene annotations and network records.  
- **Literature:** GPRC5A has been proposed as a biomarker in gastric cancer in the supplied record (PMID **40865843**), but that evidence is from another disease and does not establish a breast-cancer OS relationship.  
- **Limitation:** this program may overlap with proliferation, epithelial state, or tumor composition; a causal role is not established.

## 3. Key genes and interaction modules

The following candidates are prioritized for biological follow-up, not because external records replace the uploaded statistics, but because they represent coherent modules or mechanistically testable points.

| Candidate | Current dataset | Program and interpretation | Relationship type |
|---|---:|---|---|
| **PKMYT1** | Risk-associated; HR=1.2437685, P=1.3644851e-13, FDR=9.7437879e-10 | Cell-cycle kinase associated with the broader mitotic-risk module. | Pathway co-membership with AURKA, CDC20, TPX2, and other mitotic genes; any direct protein interaction is not established by the supplied record. |
| **AURKA–TPX2–KIF20A/PRC1 module** | All risk-associated: AURKA HR=1.1885146; TPX2 HR=1.2017253; KIF20A HR=1.2180492; PRC1 HR=1.1859845 | Strong candidate mitotic-spindle and cytokinesis module. | STRING network association; TPX2-centered and PLK1-related network evidence is present, but co-membership/network association should not be called direct physical interaction without curated physical-interaction evidence. |
| **CDC20–UBE2C–UBE2S module** | Risk-associated: CDC20 HR=1.1912581; UBE2C HR=1.2100353; UBE2S HR=1.1841829 | Ubiquitin-mediated mitotic control and cell-cycle progression. | Functional/pathway co-membership and STRING association with ANAPC2; regulatory or physical relationships are not resolved here. |
| **LARP1** | Risk-associated; HR=1.2611983, P=2.0894516e-14, FDR=4.4762322e-10 | Strongest risk HR in the table; candidate post-transcriptional growth and translation regulator. | Putative functional relationship with proliferative and RNA-regulatory genes; no direct interaction with them is supplied. |
| **STIP1** | Risk-associated; HR=1.2368966, P=1.3317026e-13, FDR=9.7437879e-10 | Protein-folding/stress and tumor-immune context candidate. | Literature co-occurrence and possible regulatory/functional association; PMID **37488801** supports prognostic relevance in pan-cancer analysis, not independent breast-cancer replication. |
| **GSK3B** | Risk-associated; HR=1.2271421, P=2.163187e-13, FDR=1.1585489e-09 | Signaling hub potentially connecting growth, apoptosis, metabolism, and Wnt/β-catenin biology. | STRING records list associations with **CTNNB1, APC, AXIN1/2, DVL1, BTRC, and FRAT1**. These are database interaction/network records; they should not all be interpreted as direct physical interactions. |
| **EZR–RACGAP1** | Both risk-associated: EZR HR=1.2269146; RACGAP1 HR=1.223506 | Cytoskeletal remodeling, cytokinesis, and potentially invasive tumor behavior. | Indirect/putative relationship through cytoskeletal and mitotic biology; direct physical interaction is not demonstrated in the supplied evidence. |
| **CPT1A** | Risk-associated; HR=1.1962357, P=1.9942828e-11, FDR=2.248606e-08 | Candidate metabolic-adaptation marker linked to fatty-acid oxidation. | Pathway association with lipid metabolism; causal metabolic dependence is unproven. |
| **FCER1A–CD1C–CD1E module** | Protective-associated: FCER1A HR=0.7932319; CD1C HR=0.81422548; CD1E HR=0.82361278 | Antigen-presenting-cell representation and potentially favorable immune context. | Cell-type co-expression and immune pathway co-membership; not a direct physical protein complex based on the supplied data. |
| **PROS1 and matrix-associated protective module** | PROS1 HR=0.83621827; OGN HR=0.80743973; LAMA2 HR=0.83003966; COL14A1 HR=0.82355765; MFAP4 HR=0.83417958 | Candidate favorable stromal/tissue-architecture state. | Extracellular-matrix co-membership and bulk-tissue co-expression; not evidence of direct physical interaction. PROS1 is discussed in a breast-cancer immune-infiltration/prognosis paper (PMID **37827342**). |

## 4. Validation priorities

### 1. Validate a proliferation-centered OS signature

- **Classification:** Biomarker; interaction/network hypothesis.
- **Why prioritize:** The most coherent risk signal is the multi-gene mitotic program, rather than any single gene.
- **Current evidence:** Coordinated risk associations across **PKMYT1, TPX2, AURKA, CDC20, UBE2C, NUSAP1, PRC1, and related genes**, all with FDR < 0.01.
- **External evidence:** GO/KEGG annotations and STRING network records support cell-cycle coherence. These are not independent cohort validation.
- **Next step:** Test a prespecified signature in an independent breast-cancer OS cohort using the same gene definitions, with adjustment for stage, molecular subtype, grade, treatment, and proliferation indices.
- **Conclusion level:** **Supported hypothesis**, pending independent statistical validation.

### 2. Determine whether the protective immune signal reflects tumor-infiltrating cells

- **Classification:** Confounding or composition check; biomarker.
- **Why prioritize:** The FCER1A/CD1C/CD1E/JCHAIN/KLRB1 pattern could represent immune abundance rather than tumor-cell-intrinsic protection.
- **Current evidence:** Multiple immune-associated genes are protective-associated, including FCER1A HR=0.7932319 and CD1C HR=0.81422548.
- **External evidence:** Tissue and immune annotations support the cell-type interpretation; PMID **37827342** provides related breast-cancer evidence for PROS1 and immune infiltration. This does not prove the current signature is immune-mediated.
- **Next step:** Estimate tumor purity and immune fractions, then validate by multiplex immunohistochemistry, flow cytometry, or single-cell/spatial RNA sequencing.
- **Conclusion level:** **Supported hypothesis** for immune composition; **insufficient evidence** for a causal protective immune mechanism.

### 3. Test whether the AURKA/TPX2/CDC20 mitotic network is functionally required

- **Classification:** Mechanistic hypothesis; therapeutic target.
- **Why prioritize:** This module has the strongest program-level consistency and multiple network connections.
- **Current evidence:** Risk associations for AURKA, TPX2, CDC20, UBE2C, UBE2S, KIF20A, and PRC1; supplied pathway records include cell cycle and mitotic nuclear division.
- **External evidence:** STRING records support network connectivity, but network connectivity is not evidence that inhibiting the module improves breast-cancer survival. Drug or clinical-trial records, where present, do not establish therapeutic efficacy.
- **Next step:** Perturb AURKA, PKMYT1, CDC20, or module hubs in breast-cancer models, measure mitotic progression, apoptosis, invasion, and response across molecular subtypes, and confirm findings in vivo.
- **Conclusion level:** **Supported hypothesis** for functional testing; **exploratory hypothesis** as a therapeutic strategy.

### 4. Test LARP1/STIP1/GSK3B as a non-mitotic risk axis

- **Classification:** Mechanistic hypothesis; biomarker.
- **Why prioritize:** These genes have comparatively high risk HRs and could capture translational control, stress adaptation, or signaling not fully explained by proliferation.
- **Current evidence:** LARP1 HR=1.2611983, STIP1 HR=1.2368966, and GSK3B HR=1.2271421, all with FDR < 1.2e-09.
- **External evidence:** GSK3B annotations support signaling, apoptosis, metabolism, and Wnt-related network biology; PMID **37488801** reports a prognostic/immune association for STIP1 in pan-cancer analysis. These sources may overlap with prior literature and do not provide breast-cancer cohort replication.
- **Next step:** Evaluate protein abundance, pathway activity, and response to gene-specific perturbation while controlling for proliferation and subtype.
- **Conclusion level:** **Exploratory hypothesis** for an independent risk axis.

### 5. Assess the protective epithelial/stromal program after clinical and purity adjustment

- **Classification:** Confounding or composition check; biomarker.
- **Why prioritize:** The COL17A1/CLDN11/LAMA2/OGN/COL14A1/MFAP4/ADAMTS8 pattern may be prognostic because it marks tissue organization, favorable epithelial differentiation, or stromal abundance.
- **Current evidence:** Many genes show concordant protective associations, including COL17A1 HR=0.79759519, OGN HR=0.80743973, and LAMA2 HR=0.83003966.
- **External evidence:** Extracellular-region and tissue-expression annotations support the biological interpretation, but no independent OS statistic is supplied.
- **Next step:** Use laser-capture or single-cell/spatial profiling, pathology-based stromal scoring, and multivariable survival models including tumor purity, grade, stage, and subtype.
- **Conclusion level:** **Supported hypothesis** as a tissue-state marker; **insufficient evidence** for a causal tumor-suppressive ECM mechanism.

## 5. Evidence grounding and conflicts

- **Direct input evidence:** The HR, P value, FDR, direction, duplicate status, and selected-gene counts come only from the supplied statistical ledger and are authoritative.
- **Pathway and ontology evidence:** The supplied KEGG/GO batch identifies cell cycle, oocyte meiosis, ubiquitin-related functions, mitotic nuclear division, and broad protein/RNA-binding categories. These annotations explain plausibility but are not new P values or formal enrichment results.
- **Network evidence:** STRING and related records support functional connectivity, including PLK1-, TPX2-, CDC20-, BUB1B-, CDK4-, and DLGAP5-centered associations. These records are not uniformly direct physical interactions and may incorporate literature, prediction, or functional association evidence.
- **Tissue and disease evidence:** Immune, epithelial, and extracellular-matrix interpretations are biologically compatible with bulk breast tumor tissue. They remain vulnerable to cell-composition effects.
- **Literature evidence:** Relevant supplied records include STIP1 and prognosis/immune infiltration (PMID **37488801**), PROS1 and breast-cancer immune infiltration/prognosis (PMID **37827342**), GPRC5A in gastric cancer (PMID **40865843**), and CENPO in hepatocellular carcinoma (PMID **36187159**). The latter two are cross-disease contextual evidence, not breast-cancer OS validation.
- **Independent statistical validation:** **Not available.** No external cohort, endpoint-specific statistic, effect estimate, confidence interval, or replication FDR was supplied. Consequently, pathway recurrence, literature support, and database coverage must not be called replication, validation, or enrichment.
- **Potential source dependence:** Pathway databases, interaction resources, and literature records can reuse the same publications or computational predictions, so their agreement does not necessarily represent independent evidence.
- **Conflict:** The principal apparent conflict is biological rather than statistical: proliferative genes are risk-associated, while immune and matrix genes are protective-associated. This is compatible with tumor heterogeneity, but the current data cannot determine whether these are tumor-intrinsic programs or compositional markers.

## 6. Major limitations and alternative explanations

1. **Tumor purity and cell composition:** Protective immune and matrix genes may reflect greater immune or stromal content, while risk genes may reflect a higher malignant-cell fraction. Investigate with purity estimates, deconvolution, pathology scoring, and single-cell or spatial assays.

2. **Clinical confounding:** Stage, grade, molecular subtype, treatment exposure, age, and metastatic burden may explain part of the HR pattern. Refit multivariable Cox models and evaluate proportional-hazards assumptions and interactions with subtype and treatment.

3. **Duplicate and correlated features:** Six duplicated gene/probe rows are retained in the ledger. Highly correlated genes can produce many apparently significant features without representing independent biological evidence. Collapse probes according to a prespecified rule and use penalized or module-level models.

4. **Statistical calibration and possible overfitting:** Uniform significance across all 100 genes is unusual. Confirm sample size, number of events, censoring, model specification, covariate handling, missing-data procedures, and whether feature selection used outcome information. Perform internal bootstrap or cross-validation followed by locked external validation.

5. **Association-versus-causation ambiguity:** A hazard ratio describes association with OS under the fitted model; it does not show that increasing a risk-associated gene worsens survival or that increasing a protective-associated gene improves it. Functional perturbation and prospective biomarker studies are required before causal or therapeutic claims.

Overall, the most defensible interpretation is a **risk-associated mitotic/proliferative program opposed by protective-associated immune and epithelial–stromal programs**, with additional signaling, stress, and metabolic components; these findings are biologically plausible and internally coherent but remain **unvalidated prognostic hypotheses** until the statistical quality concerns and independent-cohort performance are resolved.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=50, external claims checked=0, external mismatches=0, status=passed.

Answer model API: OpenAI / gpt-5.6-luna

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 100/100 selected items (records returned); cbioportal 100/100 selected items (records returned); chembl 52/100 selected items (records returned); civic 12/100 selected items (records returned); clinicaltrials 57/100 selected items (records returned); clinvar 100/100 selected items (records returned); ensembl 100/100 selected items (records returned); europepmc 990 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 98/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 99/100 selected items (records returned); humanbase 100/100 selected items (records returned); intact 99/100 selected items (partially returned; some queries failed); mygene 100/100 selected items (records returned); omnipath 65/100 selected items (records returned); opentargets 100/100 selected items (records returned); pubmed 791 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 99/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 100/100 selected items (records returned)
Local databases: gutmgene 4/100 selected items (records returned); hmdb 31/100 selected items (records returned); string 100/100 selected items (records returned); trrust 40/100 selected items (records returned)
